Kiadis Pharma Announces Successful Completion of Rhitol(TM) Phase II Clinical Study

    AMSTERDAM, January 31 /PRNewswire/ -- Oncology focused
 biopharmaceutical product development company Kiadis Pharma announced today
 that it has successfully finalized its Rhitol(TM) Phase II clinical trial
 with the last patient completing its six month treatment cycle. Rhitol(TM)
 is evaluated as treatment for patients with extensive chronic Graft versus
 Host Disease (GvHD) intolerant or resistant to standard immunosuppressive
 treatment.
 
     The current preliminary clinical results demonstrate an excellent
 safety profile for Rhitol(TM) and evidence of efficacy in the alleviation
 of the symptoms associated with chronic Graft versus Host Disease. After
 this clinical study was closed for enrollment mid 2007 Kiadis Pharma
 allowed new patients to be treated under a compassionate protocol. The
 successful completion of the Phase II clinical trial of Rhitol(TM) paves
 the way for a phase III study and Kiadis Pharma is planning to file for a
 phase III multi center clinical trial in the USA and Canada within the next
 few months.
 
     Manja Bouman, CEO Kiadis Pharma comments: "We are very pleased with the
 positive outcome of this study and the potential shown by Rhitol(TM). This
 product would fulfill a significant unmet medical need since patients with
 chronic GvHD resistant or intolerant to immunosuppressive drugs have no
 other standard treatment option available to them and this disease can
 subsequently develop into a life-threatening condition."
 
     To read the complete press releases please go to http://www.kiadis.com
 
     English release is provided by Kiadis Pharma. Equivalent translations
 are from a third party.
 
 
 

SOURCE Kiadis Pharma

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.